As the NHS continues to prioritize prevention over treatment, AI is emerging as a transformative force in early diagnosis and disease prediction.  

From blood-based proteomics and electrocardiograms to retinal scans and histopathology, AI-driven tools are redefining how healthcare professionals identify disease risk, optimize care pathways, and engage in timely intervention.  

This article synthesizes real-world studies, clinical trials, commercial innovations, and public health strategies to demonstrate how AI is empowering the NHS to advance both primary and secondary prevention, particularly for chronic and high-burden diseases. 

A Shift Toward Prevention 

The NHS 10-Year Plan, supported by subsequent frameworks like Core20PLUS5 and the Early Diagnosis Strategy, has made it clear that prevention is no longer a peripheral ambition but a central pillar of healthcare delivery. Prevention in this context includes both primary efforts (avoiding disease onset) and secondary interventions (detecting and managing early-stage disease). AI technologies, particularly those enabling early diagnosis and risk prediction, are increasingly critical to realizing this vision. 

AI in Blood-Based Risk Prediction: Unlocking Proteomic Insights 

A study published in Nature Aging led by the University of Edinburgh in collaboration with Optima Partners and Biogen used AI to analyze blood samples from the UK Biobank. Researchers identified protein patterns predictive of Alzheimer’s, heart disease, and type 2 diabetes up to a decade in advance. These patterns improved prediction accuracy beyond traditional risk factors such as age, cholesterol, and lifestyle. 

According to Dr Danni Gadd:

“It’s encouraging to see how much potential there is from a single blood sample that allow us to predict a range of disease outcomes. Being able to detect early warning signs for a broad set of conditions may lead to opportunities for early intervention and prevention, marking a significant moment for the healthcare industry.”

Dr. Chris Foley emphasized “Pattern recognition like this would not be possible without modern machine learning technology, and its capacity to analyse data at this scale, and this will in turn allow us to address some of the most pressing healthcare challenges of our time.”

Predicting Diabetes and Heart Disease from ECGs 

Aire-DM: Predicting Diabetes and Cardiac Risk from Routine ECGs 

Aire-DM, an AI model developed at Imperial College London, analyzes routine ECG data to predict type 2 diabetes up to 13 years before diagnosis. The system, trialing in 2025 at Imperial College Healthcare NHS Trust and Chelsea and Westminster Hospital NHS Foundation Trust, detects subtle electrical changes invisible to human readers. 

Initial testing has demonstrated that the model can accurately predict diabetes risk in individuals across a range of ages, genders, ethnicities, and socioeconomic groups 70% of the time. 

Professor Bryan Williams, Chief Scientific and Medical Officer of the British Heart Foundation, explained that this exciting research uses powerful artificial intelligence to analyze ECGs, revealing how AI can spot things that cannot usually be observed in routinely collected health data. 

Additionally, it can identify structural issues in the heart that may be invisible to doctors, and alert them to patients who could benefit from additional monitoring, testing, or treatment. 

Research published in The Lancet Digital Health found that Aire could correctly identify a patient’s risk of death within 10 years of an ECG in 78% of cases. The AI system was trained using data from over 1.16 million ECGs involving nearly 190,000 patients. Aire also predicted future heart failure in 79% of cases, serious heart rhythm problems in 76%, and atherosclerotic cardiovascular disease in 70% of cases. 

Dr Fu Siong Ng from Imperial College London stated that the vision is for every ECG done in a hospital to be put through the model. In the future, every ECG in the NHS may inform clinicians not just of a diagnosis but of a whole range of health risks, enabling early intervention and prevention. 

ECG-Based Early Diagnosis 

In parallel, the Mayo Clinic has developed ECG-AI algorithms that are transforming how clinicians assess cardiac risk. These models can detect a variety of issues, such as irregular heart rhythms, weakened heart pumping, thickened heart muscle, and signs of heart valve or protein-related disease.

The system can also estimate a patient’s biological age using both traditional 12-lead ECGs and single-lead recordings from smartwatches and portable devices. This opens the door to widespread, low-cost screening using consumer health technology. 

One of the most promising applications of ECG-AI is in the early detection of cardiac amyloidosis—a progressive and often underdiagnosed condition where amyloid proteins build up in the heart muscle. By identifying subtle signs of disease before symptoms appear, the system enables earlier intervention, better monitoring, and potentially improved outcomes. 

Cleerly: Redefining Cardiovascular Risk Stratification 

Cleerly is transforming cardiac care by providing non-invasive, AI-enhanced coronary phenotyping using CT imaging. Their platform enables the detection of heart disease before symptoms appear, offering a detailed characterization of plaque type and burden. Cleerly’s models are trained on millions of annotated images from over 40,000 patients.

By integrating seamlessly into cardiovascular workflows, Cleerly helps clinicians identify at-risk individuals earlier, personalize treatment, and reduce the likelihood of major adverse cardiac events.  

AI in Autism and Neurodegenerative Disorders 

AI is transforming how complex neurological conditions are identified and diagnosed at an early stage—from detecting dementia through eye scans to screening for autism using mobile applications. 

Historically, autism spectrum disorder (ASD) has been diagnosed through behavioral assessments, which often result in delays until a child reaches school age. AI is helping to close this gap by analyzing behavioral patterns, genetic markers, and neuroimaging data, enabling earlier and more precise detection. 

The NeurEye Project: A Window to Early Dementia Detection 

The NeurEye project, led by the University of Edinburgh and Glasgow Caledonian University, is analyzing nearly one million eye scans with AI to identify early markers of dementia. Ocular imaging, a routine and non-invasive procedure, offers a novel window into brain health. Data is securely hosted in the Scottish National Safe Haven, linking anonymized eye scans with relevant demographic and clinical history to build predictive models. 

“The eye can tell us far more than we thought possible. The blood vessels and neural pathways of retina and brain are intimately related. But, unlike the brain, we can see the retina with the simple, inexpensive equipment found in every high street in the UK and beyond,” said Professor Baljean Dhillon. 

Professor Miguel Bernabeu emphasized the need for equity in AI development:

“Recent advances in artificial Intelligence promise to revolutionise medical image interpretation and disease prediction. However, to develop algorithms that are equitable and unbiased, we need to train them on datasets that are representative of the whole population at risk.”

Dr Dave Powell, Chief Scientific Officer at LifeArc, commented that harnessing the potential of digital innovations in this way could ultimately save the NHS more than £37 million a year. The hope is that it will speed up the diagnosis and treatment of neurodegenerative conditions like dementia. 

Predictive Models for Behavioral Diagnosis 

Machine learning algorithms now automate ASD screening by identifying patterns in historical datasets. For example, Wall et al. developed a model using the Autism Diagnostic Interview-Revised Edition, achieving 99.97% accuracy in diagnosing children aged 13–48 months. This system reduced the required diagnostic criteria from 93 items to 7, streamlining the process for clinicians.

Similarly, Bertoncelli et al. created a predictive tool for preschoolers with cerebral palsy, linking motor skills and communication deficits to ASD with 73% accuracy. These models enable earlier referrals and interventions, critical for improving developmental outcomes. 

Community-Based Screening via Mobile Health Platforms 

To expand access, researchers have integrated AI into mobile applications. Shahamiri et al.’s convolutional neural network (CNN)-based system, deployed via a smartphone app, screens children under 36 months with 97.95% accuracy. 

AI-Driven Early Detection of Alzheimer’s Through Electronic Health Records 

Electronic health records are increasingly leveraged to detect Alzheimer’s disease years before clinical symptoms arise. A recent study from UC San Francisco used AI to analyze anonymized health data from over 5 million individuals. The system identified comorbidity clusters—including high blood pressure, cholesterol issues, vitamin D deficiency, and osteoporosis in women—that significantly correlated with future Alzheimer’s diagnoses. 

The model successfully predicted Alzheimer’s onset in 72% of individuals, up to seven years before symptoms appeared. The study’s findings highlight how AI can extract novel biological insights from routine data, supporting secondary prevention through earlier risk identification and personalized monitoring. 

From Mammograms to CT scans: Imaging-Based Cancer Prediction 

Lung Cancer Forecasting with Sybil 

At Massachusetts General Cancer Center, researchers developed Sybil, an AI model trained to forecast lung cancer up to six years in advance using low-dose chest CT scans. With accuracy rates ranging between 80% and 95% in validation cohorts, Sybil can identify high-risk patients long before radiological changes become visible to human eyes. 

Breast Cancer Risk Prediction with MIRAI 

At Mass General Brigham, researchers developed MIRAI, an AI model designed to predict the likelihood of developing breast cancer up to five years in advance using standard mammograms. Trained on a dataset of 128,000 mammograms, including 3,800 that resulted in a cancer diagnosis within five years, MIRAI identifies subtle imaging features that may indicate future cancer risk—often before radiologists can detect any abnormalities. 

What sets Sybil and MIRAI apart is their ability to function with only imaging data—no additional clinical or demographic information is required. This makes the tools ideal for integration into population-level lung cancer screening programs. 

CHIEF: A Multicancer Diagnostic and Prognostic Platform 

The CHIEF model, developed by Harvard Medical School, represents a comprehensive AI tool trained on over 15 million image segments from pathology slides. It can diagnose cancers, predict tumor origin, forecast patient survival, and identify gene mutations associated with therapy response. CHIEF outperformed existing models by up to 36% across 15 datasets contatining 11 cancer types and maintained high accuracy (up to 96%) across both biopsies and surgical specimens. 

Notably, CHIEF also discovered visual features linked to prognosis that were previously unrecognized by human pathologists. For instance, greater immune cell presence correlated with improved survival, while tumors with cellular disorganization or necrosis predicted worse outcomes. The tool’s versatility allows it to be used across diverse healthcare settings, helping to democratize access to advanced diagnostics. 

Supporting Primary Care Physicians in Early Cancer Detection 

C the Signs, an AI-driven decision support platform, is designed specifically for use in general practice. It rapidly analyzes patient symptoms, demographics, and risk factors to identify potential cancer risks and recommend appropriate diagnostic pathways. 

A recent study by the Suffolk and Northeast Essex Integrated Care Board showed that use of the tool led to a 12.3% increase in cancer detection rates without increasing diagnostic burden. By helping general practitioners navigate complex referral criteria and ensuring timely follow-ups, C the Signs supports the NHS’s cancer strategy to diagnose 75% of cancers at stage 1 or 2 by 2028.

Predicting Autoimmune Disease Progression with Genetic Risk Scoring 

At Penn State College of Medicine, scientists created the Genetic Progression Score (GPS) to identify individuals likely to transition from preclinical autoimmune markers to full-blown disease. GPS uses transfer learning to combine large-scale genetic data from genome-wide association studies with real-world clinical data from electronic health record biobanks. 

Validated in patients with rheumatoid arthritis and lupus using data from the All of Us and Vanderbilt University biobanks, GPS outperformed 20 existing risk models. It enables clinicians to identify high-risk patients earlier, allowing for targeted surveillance, timely therapeutic decisions, and optimized clinical trial recruitment — all hallmarks of secondary prevention. 

Augmenting Chest Radiograph Interpretation with AI 

AI is also transforming radiology workflows by acting as a second reader for imaging studies. In a multicenter study evaluating qXR, an AI tool developed by Qure.ai, radiologists and non-radiologists alike improved their ability to detect lung nodules in chest X-rays without an increase in false positives. 

qXR uses CNNs trained on over 50,000 annotated images and outputs a bounding circle along with a probability score for nodule detection. The study found substantial agreement between thoracic radiologists and confirmed that qXR enhanced detection accuracy. Such tools hold particular value in resource-constrained settings, where radiologist availability may be limited. 

Pandemic Preparedness: AI’s Role in Global Surveillance and Early Warning 

While AI applications have historically focused on individual patient care, recent studies underscore its importance in population health and infectious disease preparedness. A perspective paper in Nature led by the University of Oxford’s Pandemic Sciences Institute outlines several domains where AI can support pandemic response: 

• Modeling disease spread with improved precision 

• Identifying high-transmission zones using climate and mobility data 

• Detecting viral mutations through genomic surveillance 

• Integrating wearable data for real-time outbreak alerts 

AI may also help predict zoonotic spillovers and assess the cross-species transmission risk of emerging pathogens. While caution is advised regarding black-box models, the integration of AI into public health workflows offers a scalable and proactive approach to global health security. 

Disease X and AI-Based Genomic Surveillance 

An article published in the National Library of Medicine explored how AI can help detect, monitor, and forecast outbreaks of “Disease X” — a hypothetical but inevitable novel pathogen. AI techniques like CNNs and long short-term memory models were found to enhance: 

• Identification of new pathogens from genomic data 

• Prediction of transmission dynamics across species 

• Monitoring of viral mutations that may alter treatment efficacy 

These capabilities enable earlier, more coordinated responses to novel health threats and can accelerate the development of targeted vaccines and therapies. 

Additional Startups Advancing Early Detection 

Several other companies are contributing to the AI-driven early diagnosis ecosystem: 

• MedAI Insights: Predicts sepsis and heart attacks 24 hours in advance using real-time hospital data 

• NeuroHealth AI: Uses speech and motor analysis for early detection of neurodegenerative diseases 

• SmartLab Diagnostics: Applies machine learning to blood samples for rapid disease identification 

• GeneticIQ: Offers AI-powered genetic risk analysis to personalize prevention plans 

• PathAI: Uses deep learning to support the analysis of histopathology slides for early cancer detection with 99% accuracy in interpreting biopsy samples. 

• Owkin’s AI accelerates biomarker discovery and identifies patients most likely to benefit from emerging therapies. This bridges the gap between early diagnosis and personalized treatment, especially for under-researched conditions. 

Conclusion: Aligning AI with the NHS Prevention Mission 

Across the healthcare landscape, AI-driven startups are not simply introducing new tools — they are fundamentally reshaping how early detection is approached and delivered. From imaging-based coronary assessments and retinal disease interception to rapid histopathology interpretation and predictive genomics, these companies are extending the frontiers of what is clinically possible. 

Their technologies are empowering clinicians to detect disease earlier, improve diagnostic accuracy, and intervene before conditions escalate into costly, complex challenges. By integrating seamlessly into existing care pathways, these solutions offer scalable, real-world applications that align directly with the NHS’s emphasis on prevention, personalization, and health equity. 

As these innovations continue to gain clinical validation and regulatory support, they are poised to accelerate the transition toward a more proactive, data-informed model of care. With responsible deployment, AI tools will not only enhance clinical decision-making but also help build the infrastructure for a sustainable, prevention-first healthcare system. 

As the NHS continues to evolve toward integrated care and population health models, AI will be essential in closing diagnostic gaps, managing long-term conditions, and scaling preventive strategies that improve lives while safeguarding limited resources. Ensuring transparency, ethical deployment, and robust evaluation will be key. But the direction is clear: prevention is the future, and AI is helping build it.